Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity
The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January...
Gespeichert in:
| Veröffentlicht in: | Virologica Sinica 2020-12, Vol.35 (6), p.752-757 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 757 |
|---|---|
| container_issue | 6 |
| container_start_page | 752 |
| container_title | Virologica Sinica |
| container_volume | 35 |
| creator | Kong, Wen-Hua Zhao, Rong Zhou, Jun-Bo Wang, Fang Kong, De-Guang Sun, Jian-Bin Ruan, Qiong-Fang Liu, Man-Qing |
| description | The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February, 2020, including 32 severe/critical cases and 56 mild/moderate cases. Their mean age was 56.43 years (range 17–83) and gender ratio (male/female) was 43:45. We tested SARS-CoV-2 RNA with commercial kits, investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using magnetic particle chemiluminescence immunoassays, and compared the results of serologic tests and nucleic acid test (NAT). Among 88 patients, 95.45% were confirmed as positive by the combination of NAT and antibody test, which was significantly higher (
P
|
| doi_str_mv | 10.1007/s12250-020-00270-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7376096</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2427302290</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-3c87dabe964d36dd16488e72fd35862b253910d7fad9400d823e56845d1987be3</originalsourceid><addsrcrecordid>eNp9kU1vFDEMhiNERUvhD3BAkbhwCXWSydcFqdryUalVURcqbtHsxLNNNTtZktnS_nsCW1rgwMGKIz9-besl5AWHNxzAHBQuhAIGogYIA-zmEdnjzilmBXx9XHNtGgZGu13ytJQrAC2slE_Irqy0UkbtkdM55jSkZezoOZZ1GgvSKdH54fmczdIFEzSOdHZ2cXzEuKOf2iniOBX6PU6X9Cj2Peb6p3O8xhyn22dkp2-Hgs_v3n3y5f27z7OP7OTsw_Hs8IR1jWkmJjtrQrtAp5sgdQhcN9aiEX2QymqxEEo6DsH0bXANQLBCotK2UYE7axYo98nbre56s1hh6OoOuR38OsdVm299aqP_uzLGS79M195Io8HpKvD6TiCnbxssk1_F0uEwtCOmTfGiEUaCEA4q-uof9Cpt8ljPq5RxFqSTqlJiS3U5lZKxv1-Gg__plt-65atb_pdb_qY2vfzzjPuW3_ZUQG6BUkvjEvPD7P_I_gCfCp52</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2479803935</pqid></control><display><type>article</type><title>Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Kong, Wen-Hua ; Zhao, Rong ; Zhou, Jun-Bo ; Wang, Fang ; Kong, De-Guang ; Sun, Jian-Bin ; Ruan, Qiong-Fang ; Liu, Man-Qing</creator><creatorcontrib>Kong, Wen-Hua ; Zhao, Rong ; Zhou, Jun-Bo ; Wang, Fang ; Kong, De-Guang ; Sun, Jian-Bin ; Ruan, Qiong-Fang ; Liu, Man-Qing</creatorcontrib><description>The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February, 2020, including 32 severe/critical cases and 56 mild/moderate cases. Their mean age was 56.43 years (range 17–83) and gender ratio (male/female) was 43:45. We tested SARS-CoV-2 RNA with commercial kits, investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using magnetic particle chemiluminescence immunoassays, and compared the results of serologic tests and nucleic acid test (NAT). Among 88 patients, 95.45% were confirmed as positive by the combination of NAT and antibody test, which was significantly higher (
P
< 0.001) than by single nucleic acid test (73.86%) or serologic test (65.91%). Then the correlation between temporal profile and the level of antibody response was analyzed. It showed that seroconversion started on day 5 after disease onset and IgG level was rose earlier than IgM. Comparison between patients with different disease severity suggested early seroconversion and high antibody titer were linked with less severe clinical symptoms. These results supported the combination of serologic testing and NAT in routine COVID-19 diagnosis and provided evidence on the temporal profile of antibody response in patients with different disease severity.</description><identifier>ISSN: 1674-0769</identifier><identifier>ISSN: 1995-820X</identifier><identifier>EISSN: 1995-820X</identifier><identifier>DOI: 10.1007/s12250-020-00270-x</identifier><identifier>PMID: 32705575</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies ; Antibodies, Viral - immunology ; Antibody Formation ; Antibody response ; Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Chemiluminescence ; China - epidemiology ; Coronaviridae ; Coronaviruses ; COVID-19 ; COVID-19 - blood ; COVID-19 - epidemiology ; COVID-19 - immunology ; COVID-19 - virology ; COVID-19 Nucleic Acid Testing - methods ; COVID-19 Serological Testing - methods ; Female ; Humans ; Immunoglobulin G ; Immunoglobulin G - blood ; Immunoglobulin G - immunology ; Immunoglobulin M ; Immunoglobulin M - blood ; Immunoglobulin M - immunology ; Luminescent Measurements - methods ; Male ; Medical Microbiology ; Microbial Genetics and Genomics ; Microbiology ; Middle Aged ; Oncology ; Pandemics ; Real-Time Polymerase Chain Reaction - methods ; Research Article ; Ribonucleic acid ; RNA ; SARS-CoV-2 - genetics ; SARS-CoV-2 - immunology ; Seroconversion ; Severe acute respiratory syndrome coronavirus 2 ; Virology ; Young Adult</subject><ispartof>Virologica Sinica, 2020-12, Vol.35 (6), p.752-757</ispartof><rights>Wuhan Institute of Virology, CAS 2020</rights><rights>Wuhan Institute of Virology, CAS 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-3c87dabe964d36dd16488e72fd35862b253910d7fad9400d823e56845d1987be3</citedby><cites>FETCH-LOGICAL-c474t-3c87dabe964d36dd16488e72fd35862b253910d7fad9400d823e56845d1987be3</cites><orcidid>0000-0002-9754-3102</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376096/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376096/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32705575$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kong, Wen-Hua</creatorcontrib><creatorcontrib>Zhao, Rong</creatorcontrib><creatorcontrib>Zhou, Jun-Bo</creatorcontrib><creatorcontrib>Wang, Fang</creatorcontrib><creatorcontrib>Kong, De-Guang</creatorcontrib><creatorcontrib>Sun, Jian-Bin</creatorcontrib><creatorcontrib>Ruan, Qiong-Fang</creatorcontrib><creatorcontrib>Liu, Man-Qing</creatorcontrib><title>Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity</title><title>Virologica Sinica</title><addtitle>Virol. Sin</addtitle><addtitle>Virol Sin</addtitle><description>The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February, 2020, including 32 severe/critical cases and 56 mild/moderate cases. Their mean age was 56.43 years (range 17–83) and gender ratio (male/female) was 43:45. We tested SARS-CoV-2 RNA with commercial kits, investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using magnetic particle chemiluminescence immunoassays, and compared the results of serologic tests and nucleic acid test (NAT). Among 88 patients, 95.45% were confirmed as positive by the combination of NAT and antibody test, which was significantly higher (
P
< 0.001) than by single nucleic acid test (73.86%) or serologic test (65.91%). Then the correlation between temporal profile and the level of antibody response was analyzed. It showed that seroconversion started on day 5 after disease onset and IgG level was rose earlier than IgM. Comparison between patients with different disease severity suggested early seroconversion and high antibody titer were linked with less severe clinical symptoms. These results supported the combination of serologic testing and NAT in routine COVID-19 diagnosis and provided evidence on the temporal profile of antibody response in patients with different disease severity.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies</subject><subject>Antibodies, Viral - immunology</subject><subject>Antibody Formation</subject><subject>Antibody response</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Chemiluminescence</subject><subject>China - epidemiology</subject><subject>Coronaviridae</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - blood</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - virology</subject><subject>COVID-19 Nucleic Acid Testing - methods</subject><subject>COVID-19 Serological Testing - methods</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - blood</subject><subject>Immunoglobulin G - immunology</subject><subject>Immunoglobulin M</subject><subject>Immunoglobulin M - blood</subject><subject>Immunoglobulin M - immunology</subject><subject>Luminescent Measurements - methods</subject><subject>Male</subject><subject>Medical Microbiology</subject><subject>Microbial Genetics and Genomics</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Pandemics</subject><subject>Real-Time Polymerase Chain Reaction - methods</subject><subject>Research Article</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>SARS-CoV-2 - genetics</subject><subject>SARS-CoV-2 - immunology</subject><subject>Seroconversion</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Virology</subject><subject>Young Adult</subject><issn>1674-0769</issn><issn>1995-820X</issn><issn>1995-820X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1vFDEMhiNERUvhD3BAkbhwCXWSydcFqdryUalVURcqbtHsxLNNNTtZktnS_nsCW1rgwMGKIz9-besl5AWHNxzAHBQuhAIGogYIA-zmEdnjzilmBXx9XHNtGgZGu13ytJQrAC2slE_Irqy0UkbtkdM55jSkZezoOZZ1GgvSKdH54fmczdIFEzSOdHZ2cXzEuKOf2iniOBX6PU6X9Cj2Peb6p3O8xhyn22dkp2-Hgs_v3n3y5f27z7OP7OTsw_Hs8IR1jWkmJjtrQrtAp5sgdQhcN9aiEX2QymqxEEo6DsH0bXANQLBCotK2UYE7axYo98nbre56s1hh6OoOuR38OsdVm299aqP_uzLGS79M195Io8HpKvD6TiCnbxssk1_F0uEwtCOmTfGiEUaCEA4q-uof9Cpt8ljPq5RxFqSTqlJiS3U5lZKxv1-Gg__plt-65atb_pdb_qY2vfzzjPuW3_ZUQG6BUkvjEvPD7P_I_gCfCp52</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Kong, Wen-Hua</creator><creator>Zhao, Rong</creator><creator>Zhou, Jun-Bo</creator><creator>Wang, Fang</creator><creator>Kong, De-Guang</creator><creator>Sun, Jian-Bin</creator><creator>Ruan, Qiong-Fang</creator><creator>Liu, Man-Qing</creator><general>Springer Singapore</general><general>KeAi Publishing Communications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9754-3102</orcidid></search><sort><creationdate>20201201</creationdate><title>Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity</title><author>Kong, Wen-Hua ; Zhao, Rong ; Zhou, Jun-Bo ; Wang, Fang ; Kong, De-Guang ; Sun, Jian-Bin ; Ruan, Qiong-Fang ; Liu, Man-Qing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-3c87dabe964d36dd16488e72fd35862b253910d7fad9400d823e56845d1987be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies</topic><topic>Antibodies, Viral - immunology</topic><topic>Antibody Formation</topic><topic>Antibody response</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Chemiluminescence</topic><topic>China - epidemiology</topic><topic>Coronaviridae</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - blood</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - virology</topic><topic>COVID-19 Nucleic Acid Testing - methods</topic><topic>COVID-19 Serological Testing - methods</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - blood</topic><topic>Immunoglobulin G - immunology</topic><topic>Immunoglobulin M</topic><topic>Immunoglobulin M - blood</topic><topic>Immunoglobulin M - immunology</topic><topic>Luminescent Measurements - methods</topic><topic>Male</topic><topic>Medical Microbiology</topic><topic>Microbial Genetics and Genomics</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Pandemics</topic><topic>Real-Time Polymerase Chain Reaction - methods</topic><topic>Research Article</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>SARS-CoV-2 - genetics</topic><topic>SARS-CoV-2 - immunology</topic><topic>Seroconversion</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Virology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kong, Wen-Hua</creatorcontrib><creatorcontrib>Zhao, Rong</creatorcontrib><creatorcontrib>Zhou, Jun-Bo</creatorcontrib><creatorcontrib>Wang, Fang</creatorcontrib><creatorcontrib>Kong, De-Guang</creatorcontrib><creatorcontrib>Sun, Jian-Bin</creatorcontrib><creatorcontrib>Ruan, Qiong-Fang</creatorcontrib><creatorcontrib>Liu, Man-Qing</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Virologica Sinica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kong, Wen-Hua</au><au>Zhao, Rong</au><au>Zhou, Jun-Bo</au><au>Wang, Fang</au><au>Kong, De-Guang</au><au>Sun, Jian-Bin</au><au>Ruan, Qiong-Fang</au><au>Liu, Man-Qing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity</atitle><jtitle>Virologica Sinica</jtitle><stitle>Virol. Sin</stitle><addtitle>Virol Sin</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>35</volume><issue>6</issue><spage>752</spage><epage>757</epage><pages>752-757</pages><issn>1674-0769</issn><issn>1995-820X</issn><eissn>1995-820X</eissn><abstract>The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February, 2020, including 32 severe/critical cases and 56 mild/moderate cases. Their mean age was 56.43 years (range 17–83) and gender ratio (male/female) was 43:45. We tested SARS-CoV-2 RNA with commercial kits, investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using magnetic particle chemiluminescence immunoassays, and compared the results of serologic tests and nucleic acid test (NAT). Among 88 patients, 95.45% were confirmed as positive by the combination of NAT and antibody test, which was significantly higher (
P
< 0.001) than by single nucleic acid test (73.86%) or serologic test (65.91%). Then the correlation between temporal profile and the level of antibody response was analyzed. It showed that seroconversion started on day 5 after disease onset and IgG level was rose earlier than IgM. Comparison between patients with different disease severity suggested early seroconversion and high antibody titer were linked with less severe clinical symptoms. These results supported the combination of serologic testing and NAT in routine COVID-19 diagnosis and provided evidence on the temporal profile of antibody response in patients with different disease severity.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>32705575</pmid><doi>10.1007/s12250-020-00270-x</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-9754-3102</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1674-0769 |
| ispartof | Virologica Sinica, 2020-12, Vol.35 (6), p.752-757 |
| issn | 1674-0769 1995-820X 1995-820X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7376096 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Aged, 80 and over Antibodies Antibodies, Viral - immunology Antibody Formation Antibody response Biochemistry Biomedical and Life Sciences Biomedicine Chemiluminescence China - epidemiology Coronaviridae Coronaviruses COVID-19 COVID-19 - blood COVID-19 - epidemiology COVID-19 - immunology COVID-19 - virology COVID-19 Nucleic Acid Testing - methods COVID-19 Serological Testing - methods Female Humans Immunoglobulin G Immunoglobulin G - blood Immunoglobulin G - immunology Immunoglobulin M Immunoglobulin M - blood Immunoglobulin M - immunology Luminescent Measurements - methods Male Medical Microbiology Microbial Genetics and Genomics Microbiology Middle Aged Oncology Pandemics Real-Time Polymerase Chain Reaction - methods Research Article Ribonucleic acid RNA SARS-CoV-2 - genetics SARS-CoV-2 - immunology Seroconversion Severe acute respiratory syndrome coronavirus 2 Virology Young Adult |
| title | Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T12%3A22%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serologic%20Response%20to%20SARS-CoV-2%20in%20COVID-19%20Patients%20with%20Different%20Severity&rft.jtitle=Virologica%20Sinica&rft.au=Kong,%20Wen-Hua&rft.date=2020-12-01&rft.volume=35&rft.issue=6&rft.spage=752&rft.epage=757&rft.pages=752-757&rft.issn=1674-0769&rft.eissn=1995-820X&rft_id=info:doi/10.1007/s12250-020-00270-x&rft_dat=%3Cproquest_pubme%3E2427302290%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2479803935&rft_id=info:pmid/32705575&rfr_iscdi=true |